Lanean...
Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics
Immune checkpoint blockade (ICB) therapy elicits antitumor response by inhibiting immune suppressor components, including programmed cell death protein 1 and its ligand (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Despite improved therapeutic efficacy, the clinical response...
Gorde:
| Argitaratua izan da: | Acc Chem Res |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8177058/ https://ncbi.nlm.nih.gov/pubmed/33073988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.accounts.0c00339 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|